The production and release of chemical substances into the environment continue to increase in modern society. Compounds known as endocrine-disrupting chemicals (EDCs) are a heterogeneous group of contaminants present in the environment and in food that may interfere with the endocrine and reproductive system even at low doses ([@b29-ehp-118-427]). They may bind to hormone receptors, interfering with inhibition of synthesis and/or transport of particular hormones ([@b44-ehp-118-427]).

Alkylphenol ethoxylates, among the most important EDCs, were introduced in the 1940s and are a class of non-ionic surfactants used in detergents, paints, pesticides, personal care products, and plastics ([@b58-ehp-118-427]; [@b66-ehp-118-427]). These chemicals are discharged into aquatic environments via urban and industrial wastewaters, where they are broken down biologically to nonylphenol ethoxylate by-products and to the final degradation intermediate nonylphenol (NP) ([@b51-ehp-118-427]; [@b66-ehp-118-427]). These metabolites are also used as intermediates in the chemical industry ([@b42-ehp-118-427]).

*para*-Nonylphenol (*p*-NP), a representative alkylphenol widely used in detergents, emulsifiers, and solubilizers, accumulates in the environment, where it acts with estrogen-like activity ([@b14-ehp-118-427]; [@b62-ehp-118-427]). Human exposure to *p*-NP may occur by cutaneous absorption, ingestion of contaminated food or water, and inhalation ([@b22-ehp-118-427]; [@b40-ehp-118-427]). Several studies have shown that *p*-NP binds to both estrogen receptor isoforms (ERα, ERβ), competing with the natural estrogen 17β-estradiol (17β-E~2~) ([@b31-ehp-118-427]; [@b59-ehp-118-427]; [@b66-ehp-118-427]), although with less potency ([@b5-ehp-118-427]; [@b43-ehp-118-427]). Estrogenic activity of *p*-NP has been reported in both *in vitro* studies ([@b58-ehp-118-427]; [@b66-ehp-118-427]) and *in vivo* studies ([@b33-ehp-118-427]). Induction of estrogen and progesterone receptor synthesis and proliferation of breast cancer cells (MCF-7) have been known since 1991 ([@b58-ehp-118-427]), and tumorigenesis in estrogen-sensitive target tissues has been reported in the last 10 years ([@b4-ehp-118-427]; [@b57-ehp-118-427]). Studies in rats have shown that subcutaneous injection of *p*-NP in late pregnancy induces calbindin-D9k (CaBP-9k) mRNA and protein expression in maternal and neonatal uteri, suggesting its potential transfer through the placenta ([@b24-ehp-118-427], [@b25-ehp-118-427]). CaBP-9k is a cytosolic calcium-binding protein expressed in various tissues (e.g., intestine, uterus, and placenta) and a marker of estrogenic compounds exposure ([@b11-ehp-118-427]). Human placenta is an estrogen target tissue expressing both ERα and ERβ ([@b3-ehp-118-427]; [@b17-ehp-118-427]; [@b48-ehp-118-427]), so it is an interesting model to study the estrogen-like activity of *p*-NP. Using an *in vitro* model of chorionic villous explants, we recently demonstrated that *p*-NP has an estrogen-like activity on first-trimester human placenta, with a higher potency than 17β-E~2~ ([@b3-ehp-118-427]). In particular, exposure to a low concentration of *p*-NP (10^−9^ M) caused an increase of trophoblast differentiation and cell apoptosis.

Placental establishment and development are physiologic processes closely regulated by soluble autocrine/paracrine factors, namely, cytokines ([@b37-ehp-118-427]; [@b50-ehp-118-427]; [@b60-ehp-118-427]). They include interferons (IFNs), interleukins (ILs), colony-stimulating factors (CSFs), tumor necrosis factors (TNFs), chemokines, transforming growth factors, and leukemia inhibitory factors ([@b64-ehp-118-427]). Many studies conducted in humans and mice have established that a correct balance of cytokines at the maternal--fetal interface is an essential requirement for proper placental development and therefore reproductive success ([@b8-ehp-118-427]; [@b10-ehp-118-427]; [@b13-ehp-118-427]; [@b32-ehp-118-427]; [@b47-ehp-118-427]). Alkylphenols, particularly *p*-NP, also act in immune T cells by altering cytokine synthesis in mice ([@b27-ehp-118-427]; [@b34-ehp-118-427], [@b35-ehp-118-427]).

The aim of the present study was to investigate whether *in vitro* exposure to low concentrations of *p*-NP (from 10^−13^ to 10^−9^ M), even lower than those found in the environment ([@b56-ehp-118-427]), can interfere with placental secretion of cytokines.

Materials and Methods
=====================

Sample collection
-----------------

Placental tissues from first-trimester pregnancies (*n* = 6) were obtained at the hospital's Division of Obstetrics and Gynecology (Campostaggia, Siena, Italy). Only healthy women who underwent elective termination of pregnancy at weeks 7--8 of gestation were included into the study. Written informed consent after full explanation of the purpose of the study was obtained by the physician from each enrolled patient. Gestational age was determined by the date of the last menstrual period and ultrasound measurement of crown--rump length. When there was a discrepancy of ≥ 7 days between the two dating methods, patients were excluded from the study. Tissues were rinsed in cold phosphate-buffered saline (PBS) to remove excessive blood and processed for explant cultures within 2 hr. The present study was approved by the local ethics committee (Siena, May 2004) in accordance with the Helsinki Declaration guidelines.

Isolation and treatment of chorionic villous explants
-----------------------------------------------------

Villous explants from placental tissues were dissected as described by [@b7-ehp-118-427]. Briefly, small fragments of villous tips (15--20 mg wet weight) were placed on Millicell CM culture dish inserts (Millipore Corp., Bedford, MA, USA) previously coated with 180 μL undiluted Matrigel (Collaborative Research, Inc., Bedford, MA, USA) and then inserted in 24-well plates and left overnight at 37°C in a humidified atmosphere of 95% air/5% CO~2~ to allow explant attachment to the Matrigel. After this time, explants were exposed to culture medium containing *p*-NP (Sigma Chemical Co., St. Louis, MO, USA) at 10^−13^, 10^−11^, and 10^−9^ M, or only to vehicle (0.1% ethanol; control cultures) for 24 hr. *p*-NP concentrations and incubation time were selected on the basis of a report by [@b3-ehp-118-427] showing trophoblast differentiation and cell apoptosis on *p*-NP exposure. The culture medium used was Dulbecco's modified Eagle's medium/F12 without phenol red (Gibco, Grand Island, NY, USA) supplemented with 100 U/mL penicillin/streptomycin and 2 mM l-glutamine (Sigma). At 24 hr of incubation, explants were removed from the Matrigel, washed in PBS, frozen, and stored at −80°C until processing for protein extraction. Culture medium was centrifuged at 4°C for 10 min at 10,000 × *g*, divided into aliquots, immediately frozen at −80°C, and maintained frozen until analysis for cytokines and β-human chorionic gonadotropin (β-hCG). In total, six experiments were performed, each using a single placenta. *p*-NP treatments and control cultures were carried out in triplicate, and samples from separate explant cultures were pooled before being processed at the end of incubation.

Protein extraction
------------------

Pooled villous explants from each treatment were homogenized in ice-cold lysing buffer (50 mM Tris-HCl, 50 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate) containing 100 mM sodium orthovanadate and a protease inhibitor cocktail containing 4-(2-aminoethyl benzenesulfonyl fluoride), pepstatin A, E-64, bestatin, leupeptin, and aprotinin (Sigma). Protein lysates were clarified by centrifuging at 13,000 × *g* for 15 min at 4°C. Total protein concentration (mg/mL) was determined by the Quick Start Bradford Protein Assay (Biorad Laboratories, Hercules, CA, USA).

Multiplex assay for cytokine quantification
-------------------------------------------

Ten cytokines released into the chorionic explant culture medium were measured simultaneously with the Human Ultrasensitive Cytokine 10-Plex Multiplex Bead Immunoassay (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol. The range of detection was 0.75--549 pg/mL for granulocyte-macrophage colony--stimulating factor (GM-CSF), 0.71--515 pg/mL for IFN-γ, 0.38--274 pg/mL for IL-1β, 0.46--333 pg/mL for IL-2, 1.4--1,019 pg/mL for IL-4, 1.26--916 pg/mL for IL-5, 0.56--409 pg/mL for IL-6, 0.65--474 pg/mL for IL-8, 0.45--330 pg/mL for IL-10, and 0.51--369 pg/mL for TNF-α. These values represent the lowest and the highest limit of detection (LOD) for each cytokine, and concentrations outside the LOD were not considered for statistical analysis. We calculated cytokine concentrations in the samples using a standard curve established from serial dilutions of each cytokine standard as described in the manufacturer's protocol and expressed as picograms per milliliter of culture medium. Cytokine concentrations were normalized to total explant protein content and expressed as picograms per milligram of tissue protein.

β-hCG assay
-----------

The concentration of β-hCG in the explant culture medium was assessed with a commercial immunoenzymometric assay (Radim SpA, Pomezia, Italy) following the manufacturer's instructions. The limit of sensitivity was 2 mIU/mL and the linear range of detection was 0--2,000 mIU/mL. The concentration was expressed in milli-international units per microgram of total protein in tissue explants.

Statistical analysis
--------------------

The effect of *p*-NP on cytokine secretion was expressed as the stimulatory index (SI): the ratio between the cytokine concentration in the culture medium of *p*-NP--treated explant cultures and the corresponding control cultures in each experiment. We used SI for statistical analysis instead of normalized values to examine differences and trends among our data. Analyses were performed with SPSS \[version 13 (SPSS Inc., Chicago, IL, USA) for Mac OS X Tiger (version 10.4.11; Apple, Cologno Monzese, MI, Italy)\]. The Shapiro--Wilk test and Q-Q plots were used to confirm normality; Levene's test and detrended Q-Q plots were respectively used to confirm homoskedasticity and the lack of outliers. Statistically significant differences were determined by one-way analysis of variance (*p* ≤ 0.05).

Results
=======

Detection of cytokines
----------------------

We analyzed 24 samples, including three *p*-NP treatments (10^−13^, 10^−11^, 10^−9^ M) and one control (ethanol 0.1%) from six separate experiments, for GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and TNF-α by means of specific immunoassays. We identified GM-CSF, IFN-γ, IL-1β, and IL-4 in all samples analyzed. We detected IL-10 and TNF-α in 83.3% and 50% of all samples, respectively, whereas their levels were less than the respective LODs, \< 0.45 pg/mL and \< 0.51 pg/mL, in the other samples. IL-2 and IL-5 were below the respective LODs (\< 0.46 and \< 1.26 pg/mL), whereas IL-6 and IL-8 exceeded the respective LODs, \> 409 and \> 474 pg/mL, in 100% of the samples ([Table 1](#t1-ehp-118-427){ref-type="table"}).

Cytokines in p-NP--treated cultures
-----------------------------------

Control cultures of first-trimester human placenta exposed only to vehicle (0.1% ethanol) released GM-CSF, IFN-γ, IL-1β, IL-4, IL-6, IL-8, IL-10, and TNF-α into the culture medium (concentrations and interindividual variances reported in [Table 1](#t1-ehp-118-427){ref-type="table"}). Because the levels of IL-6 and IL-8 were above the LOD in all samples examined, we determined the concentrations of these cytokines in a separate assay running together pure and 1:10 diluted samples from a representative experiment. The concentrations of IL-6 and IL-8 were 100--1,000 times higher than those of the other cytokines ([Figure 1](#f1-ehp-118-427){ref-type="fig"}).

Treatment with *p*-NP for 24 hr increased the secretion of GM-CSF, IFN-γ, IL-1β, IL-4, and IL-10 with respect to control cultures ([Figure 2](#f2-ehp-118-427){ref-type="fig"}). We observed a biphasic effect of *p*-NP for TNF-α: It was suppressive at the lowest concentration (10^−13^ M) and stimulatory at the others, with a peak at 10^−11^ M ([Figure 2](#f2-ehp-118-427){ref-type="fig"}). To reduce the subject/tissue variability, we expressed data as the mean SI \[ratio between the cytokine concentration in culture medium of treated explant cultures and the corresponding untreated cultures (0.1% ethanol) in each experiment\]. We observed increasing SIs for GM-CSF, IFN-γ, IL-1β, IL-4, TNF-α, and IL-10, with a maximum effect at 10^−9^ M *p*-NP for GM-CSF and at 10^−11^ M *p*-NP for the other cytokines ([Figure 2](#f2-ehp-118-427){ref-type="fig"}). The increase was significant for GM-CSF and IL-10 (*p* = 0.045 and *p* = 0.011, respectively) at 10^−11^ M. IL-2 and IL-5 remained below the LOD (data not shown), whereas IL-6 and IL-8 were above the LOD and we determined their concentrations in a representative experiment as described for the control cultures. We observed only slight variations for IL-6 and IL-8 with respect to the control cultures (data not shown).

In summary, we found a general stimulatory potency of *p*-NP for GM-CSF, IFN-γ, IL-1β, IL-4, TNF-α, and IL-10 at extremely low *p*-NP concentrations, with a suppressive effect for TNF-α at 10^−13^ M *p*-NP. IL-2 and IL-5 were below the LOD in both *p*-NP--treated and control cultures. IL-6 and IL-8 were the most abundant cytokines, but their levels were not affected by *p*-NP treatment. We observed significant differences with respect to control cultures only for GM-CSF and IL-10 (*p* = 0.045 and *p* = 0.011, respectively). These results do not exclude possible differences for the other cytokines tested; they show only that the low number of samples containing detectable amounts of some cytokines and the high variability of individual measurements did not allow us to highlight the differences with a low probability of error.

Detection of β-hCG
------------------

We analyzed β-hCG secretion, a marker of trophoblast viability, by a specific immunoenzymometric assay in parallel with the cytokine assays. We detected β-hCG in 100% of the samples, with no significant difference with respect to control cultures at any of the *p*-NP concentrations (data not shown).

Discussion
==========

Cytokines play a critical role in pregnancy, particularly in the early stages during blastocyst implantation and placental development ([@b9-ehp-118-427]; [@b39-ehp-118-427]; [@b46-ehp-118-427]; [@b52-ehp-118-427]; [@b55-ehp-118-427]). Therefore, it is extremely useful to study cytokines secreted by the placenta in the first trimester of pregnancy, as well as potential interfering factors.

Using an *in vitro* model of chorionic villous explants, we showed here that *p*-NP, a ubiquitous environmental contaminant with estrogenic activity, interfered with first-trimester human placenta cytokine secretion. In particular, we assayed a set of 10 cytokines (GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and TNF-α) in the culture medium of chorionic villous explants exposed to *p*-NP or only to vehicle (control). The findings revealed an increase of GM-CSF, IFN-γ, IL-1β, IL-4, and IL-10, with a maximum activity at 10^−9^ M *p*-NP for GM-CSF and 10^−11^ M *p*-NP for the other cytokines, with a significant difference for GM-CSF and IL-10 at 10^−11^ M *p*-NP. TNF-α release was also modulated by *p*-NP treatment with a decrease at 10^−13^ M and an increase at higher *p*-NP concentrations. IL-6 and IL-8, the most abundantly secreted cytokines, were not affected by *p*-NP treatment at any concentration, whereas IL-2 and IL-5 were below the detection limit in *p*-NP--treated and untreated placental explants. To demonstrate tissue integrity in our explant cultures, we verified that β-hCG secretion did not change significantly in *p*-NP--treated versus control cultures. β-hCG release is a marker of continuous endocrine activity of the syncytiotrophoblast, the epithelial layer of chorionic villi forming the placental barrier ([@b38-ehp-118-427]). Using the same model of placental explants, we previously showed that 10^−9^ M *p*-NP had an estrogen-like effect, in that it increased β-hCG release and cellular apoptosis at 48--72 hr of *p*-NP exposure ([@b3-ehp-118-427]). In accordance with these previous findings, we found no remarkable changes in β-hCG release at 24 hr of exposure, even at 10^−9^ M *p*-NP, the highest concentration used. These data reveal that *p*-NP deregulates cytokine secretion before it acts on β-hCG release.

GM-CSF and IL-10, the two cytokines significantly affected by *p*-NP, are important mediators in human pregnancy ([@b20-ehp-118-427]; [@b49-ehp-118-427]). Indeed, GM-CSF is a pivotal factor contributing to normal placental development and fetal growth ([@b49-ehp-118-427]). It is expressed in early gestation by fetal trophoblast and by decidual immune and nonimmune cells ([@b28-ehp-118-427]; [@b54-ehp-118-427]). It also acts on placental trophoblast cells by inducing differentiation into mature syncytiotrophoblast and stimulates its secretion of placental lactogen and chorionic gonadotropin ([@b2-ehp-118-427]; [@b19-ehp-118-427]; [@b41-ehp-118-427]). A very recent report by [@b18-ehp-118-427] showed that GM-CSF-producing natural killer (NK) cells in the maternal decidua tended to be decreased in women with recurrent abortion or implantation failure. All these studies suggest that GM-CSF is a crucial autocrine/paracrine mediator at the maternal--fetal interface regulating placental growth and its acceptance in the maternal uterus.

IL-10 is an anti-inflammatory cytokine widely present in tissues and fluids during gestation ([@b20-ehp-118-427]), including cyto- and syncytiotrophoblast as well as decidual mononuclear cells/macrophages and NK cells ([@b23-ehp-118-427]; [@b36-ehp-118-427]). High levels of IL-10 have also been found in amniotic fluid and in the maternal serum ([@b16-ehp-118-427]; [@b20-ehp-118-427]; [@b21-ehp-118-427]). IL-10 is one of the cytokines produced by T-helper (Th)2 lymphocytes, whose immunity is necessary for successful fetal outcome. During pregnancy, Th1-driven cell-mediated immunity characterized by the secretion of IFN-γ, TNF-α, and IL-2 is shifted to a Th2-driven humoral immunity mainly represented by the secretion of IL-4, IL-5, IL-6, and IL-10 ([@b65-ehp-118-427]). Deviation from the Th2-like response leads to miscarriage ([@b47-ehp-118-427]; [@b63-ehp-118-427]), and the administration of Th1 cytokines in mice has also been shown to cause miscarriage ([@b63-ehp-118-427]).

The present study shows that Th2 placental cytokines (IL-4 and IL-10) are increased by *p*-NP treatment, whereas Th1 cytokines are increased, as in the case of IFN-γ, or modulated by a decrease or increase depending on the *p*-NP concentration, as in the case of TNF-α. These findings agree with [@b34-ehp-118-427] and [@b27-ehp-118-427] in showing an imbalance of Th1/Th2 cytokines in immune cells caused by *p*-NP exposure. Specifically, [@b34-ehp-118-427] demonstrated that *p*-NP increased IL-4 production in CD4^+^ T cells and [@b27-ehp-118-427] showed that *p*-NP and octylphenol had direct effects on T cells, suppressing the Th1 and enhancing the Th2 cytokine development.

The consequences of this altered balance at the maternal--fetal interface are not known. Literature reports have shown that some of the cytokines increased in this study (GM-CSF, IL-4, and IL-10) are able to stimulate β-hCG secretion by the trophoblast cells ([@b15-ehp-118-427]; [@b45-ehp-118-427]; [@b53-ehp-118-427]). These findings, along with ours, suggest that, by altering cytokine balance and therefore trophoblast differentiation, *p*-NP exposure in early gestation may contribute to faulty placentation, leading to pregnancy disorders and fetal growth retardation ([@b1-ehp-118-427]; [@b12-ehp-118-427]).

The *p*-NP concentrations used here are in the nano- to picomolar range, well below (\< 1,000 times) those reported in other *in vitro* systems or those found in humans ([@b5-ehp-118-427]; [@b26-ehp-118-427]; [@b30-ehp-118-427]; [@b43-ehp-118-427]; [@b61-ehp-118-427]). To our knowledge, no biological effects have been reported for *p*-NP at concentrations \< 1 μM, except for the recent finding of a dose-dependent inhibition of aromatase activity in human JEG-3 placenta cells in the range of 10^−9^ to 10^−5^ M ([@b6-ehp-118-427]). The present study supports the high sensitivity of human placenta to *p*-NP exposure. The most effective concentration (10^−11^ M) used in the present study is about 2.2 pg/mL, whereas the levels of *p*-NP detected in human samples vary from 0.3 to 221.7 ng/mL, and in the environment, 4.1 μg/L in river waters and 1 mg/kg in sediments ([@b26-ehp-118-427]; [@b30-ehp-118-427]; [@b56-ehp-118-427]). Lower levels have been reported (15.17 ng/mL) in human cord blood samples ([@b61-ehp-118-427]).

Conclusion
==========

Our study demonstrates that *p*-NP at environmentally relevant levels affects the cytokine balance in human placenta. Environmental levels of *p*-NP may be well above the threshold necessary to induce paracrine disruption in human placenta. These results raise concern about maternal exposure to this chemical during pregnancy and suggest a possible involvement of environmental factors in pregnancy complications.
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![Representative pie chart of cytokine concentrations in the culture medium of chorionic villous explants from human placenta at the first trimester of pregnancy exposed to 0.1% ethanol for 24 hr (control cultures). Numbers in parentheses are cytokine concentrations (pg/mg total tissue protein).](ehp-118-427f1){#f1-ehp-118-427}
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Cytokine concentration (pg/mg total tissue protein) in culture medium from *p*-NP--treated and --untreated chorionic villous explants.

  Group              GM-CSF   IFN-γ    IL-1β    IL-2     IL-4     IL-5     IL-10    TNF-α    IL-6     IL-8
  ------------------ -------- -------- -------- -------- -------- -------- -------- -------- -------- --------
  Control                                                                                             
   *n*               6        6        6        6        6        6        5        3        6        6
   Mean (pg/mg)      0.5370   0.8438   2.7867   \< LOD   1.9622   \< LOD   0.1154   0.4214   \> LOD   \> LOD
   SD                0.3251   0.7144   1.2905            1.0012            0.0965   0.2841            
   Variance          0.1060   0.5100   1.6650            1.0020            0.0090   0.0810            
                                                                                                      
  *p*-NP 10^−13^ M                                                                                    
   *n*               6        6        6        6        6        6        5        3        6        6
   Mean (pg/mg)      0.5439   0.7426   2.9217   \< LOD   2.2076   \< LOD   0.0948   0.2806   \> LOD   \> LOD
   SD                0.2215   0.4056   0.9331            0.7652            0.0423   0.1178            
   Variance          0.0490   0.1650   0.8710            0.5850            0.0020   0.0140            
                                                                                                      
  *p*-NP 10^−11^ M                                                                                    
   *n*               6        6        6        6        6        6        5        3        6        6
   Mean (pg/mg)      0.7676   1.2933   3.3403   \< LOD   2.7319   \< LOD   0.1757   0.6541   \> LOD   \> LOD
   SD                0.5036   1.0250   1.2457            1.5103            0.1570   0.8087            
   Variance          0.2540   1.0510   1.5520            2.2810            0.0250   0.6540            
                                                                                                      
  *p*-NP 10^−9^ M                                                                                     
   *n*               6        6        6        6        6        6        5        3        6        6
   Mean (pg/mg)      0.7337   1.0893   3.3070   \< LOD   2.6281   \< LOD   0.1904   0.6708   \> LOD   \> LOD
   SD                0.4666   0.8686   1.7310            1.8578            0.2024   0.4574            
   Variance          0.2180   0.7540   2.9960            3.4510            0.0410   0.2090            

\< LOD and \> LOD indicate values outside the detection limit.
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